Aequus Pharmaceuticals (CVE:AQS) touted data today from an initial proof-of-concept study of its long-acting, transdermal anti-nausea patch, AQS1303. The patch, which combines pyridoxine hydrochloride and doxylamine succinate, is intended to treat nausea and vomiting associated with pregnancy. The oral form of pyridoxine hydrochloride, Diclegis, is dosed up to four times a day. The single-dose comparative bioavailability […]
Pharmaceuticals
Eli Lilly to cut 8% of workforce in cost-cutting effort
Eli Lilly (NYSE:LLY) said today that it plans to shed 3,500 positions globally as it works to cut costs. The drugmaker estimates that the move will result in yearly savings of about $500 million, starting next year. Lilly said most of the cuts will come from a voluntary early-retirement program that it is offering the U.S., […]
Merck leads $11m round for Antidote’s trial-matching tech
Antidote Technologies said today that it inked an $11 million funding round to advance its clinical trial matching technologies. The round was led by Merck’s Global Health Innovation Fund. Existing investors Smedvig Capital and Octopus Ventures participated in the round, which is contingent upon obtaining certain regulatory clearances and is expected to close later this […]
Impax settles ‘fax-blasting’ class action suit over EpiPen alternative
Impax Laboratories (NSDQ:IPXL) will pony up $4.8 million to settle claims that it sent blasts of unsolicited faxes to Family Medicine Pharmacy advertising its epinephrine auto-injector, according to a document filed in a Alabama federal court this week. The Alabama-based pharmacy filed the proposed class action suit against Impax in January, alleging that the pharmaceutical company […]
Aerie launches Ph3 trial for Roclatan eye drug in Europe
Aerie Pharmaceuticals (NSDQ:AERI) said today that it launched its European Mercury 3 late-stage trial of Roclatan in patients with open-angle glaucoma or ocular hypertension. The eye drug is a fixed dose combination of Aerie’s Rhopressa netarsudil ophthalmic solution and a widely-used prostaglandin analogue, latanoprost. The company’s Phase III trial was designed to support regulatory approval and […]
Rebiotix raises $8.5m for microbiome therapy
Rebiotix has raised $8.5 million in a $10 million offering, according to a regulatory document that the company filed yesterday with the SEC. The offering, which consists of debt and convertible promissory notes, has garnered participation from 29 investors thus far, the company reported. Rebiotix said it is accepting minimum investments of $25,000 and that […]
Pulmatrix licenses inhaled COPD drug to Vectura
Pulmatrix (NSDQ:PULM) said today that it licensed its inhaled COPD drug to Vectura. The PUR0200 compound combines tiotropium bromide and Pulmatrix’s iSperse drug-delivery technology. Vectura plans to use its dry powder inhaler device to deliver PUR0200, the company said. “Vectura has deep experience with inhaled drugs and innovative dry powder delivery technologies which makes them an […]
Lumicell launches breast cancer, prostate cancer trials with Lum image-guided system
Lumicell said today that it is launching clinical studies in breast cancer and prostate cancer with its Lum image-guided cancer surgery system. The breast cancer trial is a pivotal study following an initial training period with surgeons, the Wellesley, Mass.-based company reported, and the prostate cancer study is a first for Lumicell and its technology. […]
Nordisk settles DOJ’s Victoza marketing suit for $59m
Novo Nordisk (NYSE:NVO) said yesterday afternoon that it inked a $58.7 million deal with the U.S. Dept. of Justice to settle an investigation into the company’s marketing practices for Victoza – its Type II diabetes drug. The agreement settles eight different lawsuits alleging that the drugmaker misled doctors by dressing salespeople as medical educators, paying physicians […]
Bellerophon Therapeutics touts Ph2 COPD trial of inhaled nitric oxide
Bellerophon Therapeutics (NSDQ:BLPH) touted data today from a Phase II trial of pulsed, inhaled nitric oxide in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease. The 10-patient trial was designed to evaluate the effects of pulsed, inhaled nitric oxide on targeted vasodilation and the chronic effect on hemodynamics and exercise capacity. The data showed […]